S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:GTHX

G1 Therapeutics Stock Forecast, Price & News

$13.00
-0.66 (-4.83%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.75
$13.29
50-Day Range
$12.14
$16.17
52-Week Range
$11.98
$37.07
Volume
771,200 shs
Average Volume
1.15 million shs
Market Capitalization
$552.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.16
30 days | 90 days | 365 days | Advanced Chart
Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


G1 Therapeutics logo

About G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Headlines

G1 Therapeutics to Participate in Two Upcoming Conferences
November 10, 2021 |  finance.yahoo.com
Analyst Ratings For G1 Therapeutics
November 4, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
Employees
122
Year Founded
N/A

Sales & Book Value

Annual Sales
$45.28 million
Book Value
$4.19 per share

Profitability

Net Income
$-99.25 million
Net Margins
-316.58%
Pretax Margin
-313.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
39,503,000
Market Cap
$552.79 million
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

761st out of 1,391 stocks

Pharmaceutical Preparations Industry

364th out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

Is G1 Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics
or view top-rated stocks.

How has G1 Therapeutics' stock been impacted by COVID-19?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GTHX stock has decreased by 10.3% and is now trading at $13.00.
View which stocks have been most impacted by COVID-19
.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for G1 Therapeutics
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.03. G1 Therapeutics had a negative trailing twelve-month return on equity of 65.66% and a negative net margin of 316.58%. During the same quarter last year, the company posted ($0.31) earnings per share.
View G1 Therapeutics' earnings history
.

What price target have analysts set for GTHX?

6 equities research analysts have issued 12 month target prices for G1 Therapeutics' shares. Their forecasts range from $19.00 to $71.00. On average, they anticipate G1 Therapeutics' share price to reach $45.67 in the next year. This suggests a possible upside of 251.3% from the stock's current price.
View analysts' price targets for G1 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Jack Bailey, President, Chief Executive Officer & Director
  • Terry L. Murdock, Chief Operating Officer
  • Jennifer K. Moses, Chief Financial Officer
  • Rajesh K. Malik, Chief Medical Officer (LinkedIn Profile)
  • David D. Elks, Head-Information Technology

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.62%), Fisher Asset Management LLC (4.10%), Lombard Odier Asset Management Switzerland SA (2.26%), BioImpact Capital LLC (2.02%), Nordea Investment Management AB (1.87%) and Goldman Sachs Group Inc. (1.62%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics
.

Which major investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Dimensional Fund Advisors LP, Morgan Stanley, Two Sigma Advisers LP, Voloridge Investment Management LLC, Jane Street Group LLC, Citigroup Inc., and Voya Investment Management LLC. Company insiders that have sold G1 Therapeutics company stock in the last year include Mark A Velleca, Rajesh Malik, and Seth Rudnick.
View insider buying and selling activity for G1 Therapeutics
or view top insider-selling stocks.

Which major investors are buying G1 Therapeutics stock?

GTHX stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Nordea Investment Management AB, Goldman Sachs Group Inc., Russell Investments Group Ltd., Lombard Odier Asset Management Switzerland SA, UBS Group AG, Rafferty Asset Management LLC, and BioImpact Capital LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $13.00.

How much money does G1 Therapeutics make?

G1 Therapeutics has a market capitalization of $552.79 million and generates $45.28 million in revenue each year. The company earns $-99.25 million in net income (profit) each year or ($3.26) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 122 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

Where are G1 Therapeutics' headquarters?

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at (919) 213-9835, via email at [email protected], or via fax at 919-741-5830.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.